ArticleJournal of molecular neuroscience : MN2013
Co-expressions of casein kinase 2 (CK2) subunits restore the down-regulation of tubulin levels and disruption of microtubule structures caused by PrP mutants.
Article in Journal of molecular neuroscience : MN, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- Emerging roles of the cellular prion protein (PrPCellular and molecular life sciences : CMLS · 2023Review
- Tubulin Cytoskeleton in Neurodegenerative Diseases-not Only Primary Tubulinopathies.Cellular and molecular neurobiology · 2023Review
- Extensive Disturbances of Intracellular Components and Dysfunctions of Biological Pathways in the Brain Tissues During Prion Infection - China's Studies.China CDC weekly · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CK2 shows disease-associated alteration in the scrapie experimental rodents and human prion diseases. In this study, mammalian expressing plasmids for human CK2 subunits, CK2α and CK2β, were generated. Immunoprecipitation assays revealed stronger signals of PrP-CK2α complexes in the HEK293 cells co-transfected with plasmids expressing CK2α and various PrP constructs, including PG5, CytoPrP, PG9, and PG12. Meanwhile, obviously weaker signals of PrP-CK2β complexes were also observed in the cells co-expressing CK2β and PrPs. Tubulin-specific Western blots and immunofluorescence assays revealed that similar as the observations in the presences of PrP-specific siRNA, the abnormal PrPs-induced reductions of tubulin and disruptions of microtubule structures were completely restored in the cells when co-expressing CK2α and CK2β. Moreover, co-expressions of CK2α and PrPs induced phosphorylation on p53 at the position of serine 6 (p53-Ser6), although much weaker than that in the cells expressing CK2α and CK2β, while expressions of either PrPs or CK2 subunits did not change the cellular p53 level or induce phosphorylation on p53 at Ser9. Our data here verify again the molecular interaction between CK2 and PrP. Co-presences of CK2 subunits restore the down-regulated tubulin and disrupted microtubule structures caused by expressions of the abnormal PrP proteins in HEK293 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.